Abstract:Our previous study has found this new BT technique could not only improve the target dose coverage, but also maintain the organ at risk (OARs) to a reasonable lower dose for advanced cervical cancer patients. The aim of this study is to explore potentially prognostic factors for survival and toxicity for the first time in the world. Sixty-three cervical cancer patients (FIGO stage IIB-IVA) who received ICBT+IMRT were retrospectively analyzed. They all received concomitent chemoradiotherapy. External body radiotherapy was performed with IMRT. A total dose of 45-50Gy was applied in 25 fractions for 5 weeks. The patients underwent 4 fractions BT at 6-6.5Gy/fraction twice a week. The targets and OARs were contoured by the professional physicians according to the GEC ESTRO recommendations. The complementary IMRT plan was delivered immediately after HDR-ICBT, with the applicator in position. D90, D100, V100, Vpd, V2xpd, volumes of target and D0.1cc, D1cc, D2cc, DICRU of OARs were recorded. CTCAE was used to evaluate the acute and late toxicities. The log-rank test and Cox regression mode were used for univariate and multivariate survival prognostic analyses. Logistic regression analysis was used for the toxic prognostic analyses. The 2-year local control rate (LC), distant metastasis free rate and overall survival rate were 94.8%, 84.9% and 91.6%. Both acute and late incidence of proctitis, rectal hemorrhage, small intestine obstruction and cystitis were low, the grade was not exceed G4 (Table 1.). None rectum and bladder perforation has occurred. The mean D90 of GTV, HR-CTV and IR-CTV were 93.3±4.3Gy, 81.8±2.5Gy, and 72.8±1.1Gy, and the mean D2cc of bladder, rectum, sigmoid and small intestine were lower than 75Gy. For BT dose, the mean D100 of GTV, HR-CTV and IR-CTV were 32.1±2.6, 23.2±2.2 and 14.7±1.3Gy, the mean V100 of HR-CTV and IR-CTV were 92.9%±1.2%, 92.7%±1.3%, and the mean DICRU of rectum and bladder were 22.3±4.6Gy and 18.3±3.3Gy. The D100 of IR-CTV was a prognostic factor for LC in univariate analyses among these factors (p = 0.041), but it had no statistical significance in multivariate analysis. The DICRU of bladder was a prognostic factor for the late cystitis (p = 0.045). This promising new technique could achieve the relatively higher local control rate and lower acute and late toxicity incidence. D100 of IR-CTV might be considered as a new potentially prognostic indicator for LC. DICRU of bladder still remained a prognostic factor for late cystitis, and it might have a more important role than D2cc.Scientific Abstract 2697; TableIncidence and grade of acute and late toxicityToxicityG1-2(%)G3(%)G4-5(%)Acute proctitis30.200Acute rectal hemorrhage1.600Acute small intestinal obstruction1.600Acute cystitis15.91.60Late proctitis3.200Late small intestinal obstruction1.61.60Late cystitis4.81.60Late rectal hemorrhage000 Open table in a new tab

Treatment of metastatic, imatinib refractory, gastrointestinal stroma tumor with image-guided high-dose-rate interstitial brachytherapy

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

Imatinib Mesylate Alone for Refractory Advanced Gastrointestinal Stromal Tumor

Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours (Gists)

Efficacy and Safety of the Imatinib in the Treatment of 73 Gastrointestinal Stromal Tumors

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure

Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy

Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome

Prognostic Factors For Toxicity And Survival In Advanced Cervical Cancer Patients Treated With High-Dose-Rate (Hdr)-Intracavitary Brachytherapy (Icbt) Combined With Complementary Intensity Modulated Radiation Therapy (Imrt)

Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers

The Preliminary Results of 3-Dimensional Printed Individual Template Assisted 192ir High-Dose Rate Interstitial Brachytherapy for Central Recurrent Gynecologic Cancer

Real World Treatment Patterns of Gastrointestinal Stromal Tumor Patients

A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors

Outcome of Adult Brain Tumor Consortium (ABTC) prospective dose-finding trials of I-125 balloon brachytherapy in high-grade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar

The long-term efficacy of imatinib with hepatic resection or other local treatment for gastrointestinal stromal tumours liver metastases: a retrospective cohort study

Clinical Experience in Diagnosis and Treatment of Malignant Gastrointestinal Stromal Tumors